146 related articles for article (PubMed ID: 22413476)
1. [Case report: Reversible posterior leukoencephalopathy associated with the treatment of multiple myeloma: a case report].
Ohya E; Mizutani M; Sekine T
Nihon Naika Gakkai Zasshi; 2012 Jan; 101(1):168-71. PubMed ID: 22413476
[No Abstract] [Full Text] [Related]
2. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide in renal insufficiency--balancing the risks and benefits.
Borrello I
Br J Haematol; 2009 Feb; 144(3):446-7; author reply 447-8. PubMed ID: 19120361
[No Abstract] [Full Text] [Related]
4. Posterior reversible encephalopathy syndrome in a patient with multiple myeloma treated with thalidomide.
Chow S; Cheung CS; Lee DH; Howson-Jan K; Xenocostas A
Leuk Lymphoma; 2012 May; 53(5):1003-5. PubMed ID: 22054288
[No Abstract] [Full Text] [Related]
5. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
[No Abstract] [Full Text] [Related]
6. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Dimopoulos MA; Christoulas D; Roussou M; Kastritis E; Migkou M; Gavriatopoulou M; Matsouka C; Mparmparoussi D; Psimenou E; Grapsa I; Efstathiou E; Terpos E
Eur J Haematol; 2010 Jul; 85(1):1-5. PubMed ID: 20192988
[TBL] [Abstract][Full Text] [Related]
7. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
[No Abstract] [Full Text] [Related]
8. Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.
Morita Y; Shimada T; Yamaguchi T; Rai S; Hirase C; Emoto M; Serizawa K; Taniguchi Y; Ojima M; Tatsumi Y; Ashida T; Matsumura I
Int J Hematol; 2011 Dec; 94(6):583-4. PubMed ID: 22127558
[No Abstract] [Full Text] [Related]
9. Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
Seki JT; Banglawala S; Lentz EM; Reece DE
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):162-5. PubMed ID: 23103087
[No Abstract] [Full Text] [Related]
10. Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report.
Walavalkar V; Adey DB; Laszik ZG; Jen KY
Transplant Proc; 2018 Apr; 50(3):873-876. PubMed ID: 29661456
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous huge hematoma in the abdominal wall after lenalidomide.
Murata Y; Endo I; Miura A; Ohashi K
Intern Med; 2011; 50(8):937. PubMed ID: 21498947
[No Abstract] [Full Text] [Related]
12. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA
Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563
[TBL] [Abstract][Full Text] [Related]
13. How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide.
Kastritis E; Dimopoulos M
Leuk Lymphoma; 2007 Dec; 48(12):2295-7. PubMed ID: 18066998
[No Abstract] [Full Text] [Related]
14. Current therapy of myeloma induced renal failure.
Gertz MA
Leuk Lymphoma; 2008 May; 49(5):833-4. PubMed ID: 18452070
[No Abstract] [Full Text] [Related]
15. Neutrophilic dermatosis complicating lenalidomide therapy.
Thieu KP; Rosenbach M; Xu X; Kist JM
J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
[TBL] [Abstract][Full Text] [Related]
16. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Dimopoulos MA; Cheung MC; Roussel M; Liu T; Gamberi B; Kolb B; Derigs HG; Eom H; Belhadj K; Lenain P; Van der Jagt R; Rigaudeau S; Dib M; Hall R; Jardel H; Jaccard A; Tosikyan A; Karlin L; Bensinger W; Schots R; Leupin N; Chen G; Marek J; Ervin-Haynes A; Facon T
Haematologica; 2016 Mar; 101(3):363-70. PubMed ID: 26659916
[TBL] [Abstract][Full Text] [Related]
17. Diffuse alveolar hemorrhage associated with lenalidomide.
Sakai M; Kubota T; Kuwayama Y; Ikezoe T; Yokoyama A
Int J Hematol; 2011 Jun; 93(6):830-831. PubMed ID: 21573890
[No Abstract] [Full Text] [Related]
18. Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment.
Wedel W; Sofronescu AG
Am J Clin Pathol; 2015 Aug; 144(2):329-32. PubMed ID: 26185319
[TBL] [Abstract][Full Text] [Related]
19. Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma.
Tannemaat MR; Vries EP; Molendijk WJ; Haan J
Clin Neurol Neurosurg; 2011 Jul; 113(6):488-9. PubMed ID: 21315504
[No Abstract] [Full Text] [Related]
20. Myeloma and second primary cancers.
Landgren O; Thomas A; Mailankody S
N Engl J Med; 2011 Dec; 365(23):2241-2. PubMed ID: 22150057
[No Abstract] [Full Text] [Related]
[Next] [New Search]
